Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Study Phase- Phase II Study Type- Interventional Study Design- This is an open label, non-randomized phase II study in patients with non-metastatic HER-2 positive breast cancer by FISH diagnosed in 2004 or thereafter. Potential patients will sign a written ICF prior to completing a questionnaire designed to determine what factors may affect a patient's acceptance of Herceptin® treatment. After answering the questionnaire, patients will be given the following options: 1. to receive one year of trastuzumab treatment and annual follow-up for 5 years 2. to decline trastuzumab treatment but serve as a comparison group member for monitoring safety and effectiveness of trastuzumab and to have annual follow-up for 5 years